NKNader Khalidi

Nader Khalidi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nader Khalidi has a total of 393 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploration of the genetic architecture of ANCA-associated vasculitis

    by Jinyoung Byun, Vikram R. Shaw, Catherine Zhu, Younghun Han, Ryan Sun, Zhihui Zhang, Xiangjun Xiao, Benjamin D. Pinder, Jinyi Zhang, Yohannes Tadesse, et al.

  • Altered peripheral γδT cell profiles with increased IL-17A secretion in patients with eosinophilic granulomatosis with polyangiitis

    by Nadia Suray Tan, Kate Miyasaki, Brian Kim, Carmen Venegas Garrido, Sarita Thawanaphong, Chynna Huang, Melanie Kjarsgaard, Yinglan Xie, Katherine Radford, Michael Trus, et al.

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg–Strauss Syndrome, is a rare autoimmune vasculitis with an incidence of 2.4-6.8 cases per million annually.1 It is class...

  • Open Access

    Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis

    by Manali Mukherjee, Nadia Suray Tan, Chynna Huang, Brian Kim, Katherine Radford, Xiaotian Ju, Carmen Venegas Garrido, Melanie Kjarsgaard, Eva Rodríguez-Suárez, Michael E. Wechsler, et al.

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterised by eosinophilic inflammation and autoimmune features, with anti-neutrophil cytoplasmic antibodies (ANCA) against myeloperoxidase (MPO) (pANCA) detectable in serum in up to 40% of patients. Seronegative EGPA can be associated with severe cardiac and pulmonary complications, including uncontrolled asthma [1]. We previously observed ANCA in sputum (spANCA) in 74% of EGPA patients, regardless of serum pANCA status, all of whom had severe asthma requiring high-dose oral corticosteroids [2].


  • Open Access

    Immune checkpoint inhibitor associated vasculitis and polymyalgia rheumatica: a case series and systematic review

    by Aaron Teel, Adrian Grebowicz, Yuliya Lytvyn, Stephanie Garner, C. Thomas Appleton, Alexandra P. Saltman, Nader Khalidi, Mats Junek, Faiza Khokhar

    Immune checkpoint inhibitors (ICIs) have been associated with immune-related adverse events (irAEs), including ICI associated vasculitis (ICI-vasculitis) and ICI associated PMR (ICI-polymyalgia rheumatica (PMR)-like syndromes). We sought to describe the characteristics of ICI-vasculitis and ICI-PMR in individuals treated with ICIs through a systematic review and local case series. We searched MEDLINE and Embase from inception to July 2023 for cases of ICI-vasculitis and ICI-PMR in ICI-treated individuals. Our series included cases obtained from clinicians at the Universities of Toronto, McMaster, and Western in Ontario, Canada. One hundred and forty-four patients were identified: 130 from the systematic review in 76 articles and 14 from our case series. This included 73 patients with ICI-vasculitis (14 large vessel, 7 ANCA-associated, 52 other) and 71 with ICI-PMR. Ninety-five per cent of patients were treated with glucocorticoids and 17% received disease-modifying antirheumatic drugs (DMARDs). Among 4 individuals with vasculitis who continued the ICI, two remitted. Of five who paused and restarted ICIs, one experienced a recurrence. Among four individuals with vasculitis who continued ICIs, two remitted. All 11 ICI-PMR cases that continued ICIs remitted; among 3 patients who paused and restarted two did not relapse and one had a relapse that improved with an increase in their dose of prednisone. ICI-vasculitis and ICI-PMR are underrecognized complications of ICIs. Glucocorticoids are effective for ICI-vasculitis and ICI-PMR. It is unclear if ICIs can be safely continued or restarted after remission of ICI-vasculitis or ICI-PMR. Limited data suggests ICIs may be resumed in individuals with non-severe ICI-vasculitis or ICI-PMR.


  • Assessment of Giant Cell Arteritis–Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada

    by Mats L. Junek, Rahul Chanchlani, Amadeo R. Rodriguez, Nader Khalidi, Amber O. Molnar

    Objective: There are limited data concerning outcomes in those with giant cell arteritis (GCA)-associated vision changes (GCAVCs). We estimated the association of intravenous (IV), compared to oral, glucocorticoids (GCs) with outcomes in GCAVCs. Methods: We conducted a retrospective cohort study at a tertiary healthcare facility in Ontario, Canada. Individuals aged ≥ 50 years with an International Classification of Diseases, 10th revision, diagnostic code for GCA associated with a healthcare visit between November 2017 to December 2023 were identified for inclusion. Diagnoses of GCA were verified as the final diagnosis of the treating clinician and were required to be supported by histologic, radiographic, and/or biochemical evidence of inflammatory vasculopathy. GCAVCs were identified by clinical assessments. Treatment exposures were defined as whether the individual was first exposed to IV or oral GCs. The primary outcome was reported visual improvement after treatment. We used logistic regression to estimate treatment effects, adjusting for demographic and disease factors. Results: In 289 patients with GCA, 77 (26.6%) had GCAVCs. Of these, 70.1% of GCAVCs led to permanent vision loss, and visual recovery was seen in 16% of participants. We found no difference in outcomes for those first treated with IV vs oral GCs (adjusted odds ratios 0.43-1.72; 95% CI 0.02-123.68). Conclusion: GCAVCs are common and frequently associated with permanent vision loss. Although the precision of our results was limited by sample size, we did not find evidence that receiving IV GCs before oral GCs was associated with visual improvement in GCAVCs.


  • Open Access

    A glossary of signs and symptoms of giant cell arteritis

    by Medha L. Soowamber, Milena Bond, Zahi Touma, Carol Langford, Catalina Sanchez-Alvarez, Andy Abril, Sibel Zehra Aydin, Frank Buttgereit, Dario Camellino, Maria C. Cid, et al.


  • Multivariable Models to Predict a Diagnosis of Giant Cell Arteritis: Systematic Review and Metaanalysis

    by Mats L. Junek, Iva Okaj, Sagar Patel, Angela Hu, Matthew A. Jessome, Deborah Koh, Seungwon Choi, Sukhreet Atwal, John Koussiouris, Johan Pushani, et al.

    Objective: Multiple models to predict a diagnosis of giant cell arteritis (GCA) have been developed to assist clinicians. We conducted a systematic review and metaanalysis of model variables and model performance. Methods: We searched PubMed, Embase, and the Cochrane Library from January 1990 to April 2024 for studies that used multivariable models to diagnose GCA. Study characteristics, patient characteristics, method of and criteria for diagnosis, and model details were extracted. A metaanalysis of individual signs and symptoms was performed using generic inverse variance. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was used to assess individual model risk of bias. Certainty of the effect estimate for each predictor was assessed using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. Results: We screened 2254 abstracts and included 44 studies. A total of 15,409 patients and 4340 diagnoses of GCA were included. Predictors with high certainty of effect and large effect size included jaw claudication, C-reactive protein elevation > 24.5 mg/L, platelets > 400 × 10 9 /L, positive temporal artery ultrasound, and presence of synovitis (predictive of a non-GCA diagnosis). Other factors classically associated with GCA, including vision loss, symptoms of polymyalgia rheumatica, and headache, were found to be predictive with lower certainty of effect. Models included were predominantly found to be at high risk of bias. Conclusion: Predictors of GCA were consistent across models; however, models were of poor methodologic quality. Future models to predict a diagnosis of GCA should be constructed with improved methodologic rigor. (PROSPERO registration: CRD42020186725)


  • Open Access

    Intracranial GCA: a comprehensive systematic review

    by Sagar Patel, Iva Okaj, Jessica Scott, Sukhreet Atwal, Colin Stark, Rabia Tahir, Nader Khalidi, Mats Junek

    Objectives: GCA is increasingly recognized to occur in intracranial vessels with unknown clinical ramifications. We identified all reported cases of intracranial GCA (ICGCA) in the literature to describe common presentations, investigations, treatments and outcomes. Methods: We conducted a systematic review using MEDLINE (Medical Literature Analysis and Retrieval System Online), Embase and PubMed databases to identify studies that reported cases of ICGCA. The study was registered on a systematic review database (PROSPERO 42023412373). We defined intracranial involvement as any vessel cranial to the dura mater that was confirmed by either histopathology or imaging. Data were summarized using descriptive statistics. Results: Of 1554 studies identified, 102 studies underwent full-text review. These studies included 340 patients with ICGCA. The median age was 73.7 (interquartile range [IQR] 71.9–77.3) and 46.9% patients were female. Presentations of ICGCA included stroke in 240 (70.6%) patients and isolated intracranial imaging or histologic changes in 67 (19.7%) patients. The most common vessels involved were 180 (52.9%) vertebrobasilar, 166 (48.8%) internal carotid and 49 (14.4%) ophthalmic arteries. Treatment was reported in 214 individuals. Glucocorticoids were administered to 210 (98.1%); tocilizumab, cyclophosphamide and methotrexate were the most common adjunctive medications. Of the 181 patients with reported follow-up outcomes, relapse occurred in 40 (22.1%) patients and 59 (32.6%) individuals died. Conclusion: Our findings suggest that ICGCA is not a rare entity and may represent a more severe manifestation of GCA. Optimal therapy for ICGCA is unknown. Structured prospective evaluation is needed to better understand this manifestation of GCA.


  • Open Access

    Plasma proteome profiling in giant cell arteritis

    by Kevin Y Cunningham, Benjamin Hur, Vinod K Gupta, Matthew J Koster, Cornelia M Weyand, David Cuthbertson, Nader A Khalidi, Curry L Koening, Carol A Langford, Carol A McAlear, et al.

    Objectives This study aimed to identify plasma proteomic signatures that differentiate active and inactive giant cell arteritis (GCA) from non-disease controls. By comprehensively profiling the plasma proteome of both patients with GCA and controls, we aimed to identify plasma proteins that (1) distinguish patients from controls and (2) associate with disease activity in GCA. Methods Plasma samples were obtained from 30 patients with GCA in a multi-institutional, prospective longitudinal study: one captured during active disease and another while in clinical remission. Samples from 30 age-matched/sex-matched/race-matched non-disease controls were also collected. A high-throughput, aptamer-based proteomics assay, which examines over 7000 protein features, was used to generate plasma proteome profiles from study participants. Results After adjusting for potential confounders, we identified 537 proteins differentially abundant between active GCA and controls, and 781 between inactive GCA and controls. These proteins suggest distinct immune responses, metabolic pathways and potentially novel physiological processes involved in each disease state. Additionally, we found 16 proteins associated with disease activity in patients with active GCA. Random forest models trained on the plasma proteome profiles accurately differentiated active and inactive GCA groups from controls (95.0% and 98.3% in 10-fold cross-validation, respectively). However, plasma proteins alone provided limited ability to distinguish between active and inactive disease states within the same patients. Conclusions This comprehensive analysis of the plasma proteome in GCA suggests that blood protein signatures integrated with machine learning hold promise for discovering multiplex biomarkers for GCA.


  • Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study

    by Omer Karadag, Ertugrul Cagri Bolek, Gizem Ayan, Aladdin J. Mohammad, Peter C. Grayson, Christian Pagnoux, Eduardo Martín‐Nares, Sara Monti, Yoshiyuki Abe, Federico Alberici, et al.

    Objective: We describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL‐PAN).Methods: Patients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease‐related damage, and survival were analyzed.Results: Three hundred fifty‐eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty‐five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow‐up, relapse occurred in 48.5% of patients. One, 5‐ and 10‐year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement.Conclusion: The spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN. image